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EDITORIAL  COMMENT
The significance of metabolic syndrome in association
with cardiovascular diseases has triggered extensive
debate,1,2 and the number of medical reports in this
area is increasing exponentially. One of several
controversial points is whether the 5 components
(elevated glucose, higher triglyceride, lowered high-
density lipoprotein [HDL] cholesterol, central obesity,
and hypertension) of metabolic syndrome, as proposed
by the Adult Treatment Panel III (ATP III) of the
National Cholesterol Education Program (NCEP),3
are equally important. This debate has even been
challenged by a new definition from the International
Diabetes Federation (IDF), which singled out central
obesity as the central core of metabolic syndrome.4
Another interesting point is whether these 5
components adequately cover the whole spectrum of
this syndrome. For example, vascular inflammation
markers such as highly sensitive C-reactive protein
(CRP) have been proposed as additional components
of metabolic syndrome.5
Metabolic syndrome is a group of risk factors that
predispose to cardiovascular disease. Many studies
have confirmed a positive association between
hyperuricemia and cardiovascular disease.6–8 As a matter
of fact, hyperuricemia was reported as one independent
predictor of future cardiovascular events in an 11-year
follow-up study from Taiwan.9 The link between
insulin resistance, the major abnormality of metabolic
syndrome, and hyperuricemia was elucidated by
Facchini et al,10 who reported that urinary uric acid
clearance decreased in proportion to increases in insulin
resistance in normal volunteers. They attributed that
to compensatory hyperinsulinemia in subjects with
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insulin resistance possibly causing decreased renal
excretion of uric acid in association with increased
sodium reabsorption. Very recently, it was reported
that uric acid reduced endothelial nitric oxide (NO)
bioavailability,11 which is essential for insulin-stimulated
glucose uptake in skeletal muscle through the NO-
dependent pathway.12 All these observations led to
the frequently asked question of whether uric acid
should be listed as one component of metabolic
syndrome.
Liou et al13 report in an article in this issue that
factor analysis showed serum uric acid concentrations
contributed little as an additional component of
metabolic syndrome. Specifically, they found that a
model loaded without uric acid explained a very similar
proportion of the total variance (62.5%), as did the
model loaded with uric acid (56.9%). It has to be
pointed out that the study population in this study
was specific for relatively healthy middle-aged men
(mean age 52 years old). Subjects with diabetes and
hypertension under medications were excluded from
analysis. Therefore, the findings from this study cannot
be generalized to other populations, such as women,
the elderly, or individuals with diabetes or hypertension
who take medications. In fact, Lee et al14 demonstrated
that women might have a higher prevalence of
hyperuricemia among elderly Taiwanese. A larger
study involving different aspects of populations is
needed. In addition, therapeutic investigations using
uric acid-lowering medications in order to further
explore the integrated and complex associations of
uric acid and other metabolic components are clearly
warranted.
©2006 Elsevier. All rights reserved.
*Correspondence to: Dr. Wayne H.H. Sheu, Division of Endocrinology and Metabolism, Taichung Veterans
General Hospital, 160, Section 3, Chung-Kang Road, Taichung 407, Taiwan, R.O.C.
E-mail: whhsheu@vghtc.gov.tw • Received: December 29, 2005 • Accepted: February 7, 2006
W.H.H. Sheu and Y.H. Tseng
J Chin Med Assoc • March 2006 • Vol 69 • No 3100
References
1. Kahn R, Buse J, Ferrannini E, Stern M, American Diabetes
Association, European Association for the Study of Diabetes
The metabolic syndrome: time for a critical appraisal: joint
statement from the American Diabetes Association and the
European Association for the Study of Diabetes. Diabetes Care
2005;28:2289–304.
2. Grundy SM, Cleeman JI, Deniels SR, Donato KA, Eckel RH,
Franklin BA, Gordon DJ, et al. Diagnosis and management of
the metabolic syndrome: an American Heart Association/
National Heart, Lung, and Blood Institute Scientific Statement.
Circulation 2005;112:2735–52.
3. Expert Panel on Detection, Evaluation, and Treatment of
High Blood Cholesterol in Adults. Executive Summary of the
Third Report of the National Cholesterol Education Program
(NCEP) Expert Panel on Detection, Evaluation, and Treatment
of High Blood Cholesterol in Adults (Adult Treatment Panel
III). JAMA 2001;285:2486–97.
4. Alberti KG, Zimmet P, Shaw J, IDF Epidemiology Task Force
Consensus Group. The metabolic syndrome: a new worldwide
definition. Lancet 2005;366:1059–62.
5. Ridker PM. Should C-reactive protein be added to metabolic
syndrome and to assessment of global cardiovascular risk?
Circulation 2004;109:2818–25.
6. Bickel C, Rupprecht HJ, Blankenberg S, Rippin G, Hafner G,
Daunhauer A, Hofmann KP, et al. Serum uric acid as an independent
predictor of mortality in patients with angiographically proven
coronary artery disease Am J Cardiol 2002;89:12–7.
7. Lehto S, Niskanen L, Ronnemaa T, Laakso M. Serum uric acid
is a strong predictor of stroke in patients with non-insulin-
dependent diabetes mellitus. Stroke 1998;29:635–9.
8. Niskanen LK, Laaksonen DE, Nyyssönen K, Alfthan G,
Lakka H-M, Lakka TA, Salonen JT. Uric acid level as a risk
factor for cardiovascular and all-cause mortality in middle-
aged men: prospective cohort study. Arch Intern Med 2004;
164:1546–51.
9. Chien KL, Hsu HC, Sung FC, Su TC, Chen MF, Lee YT.
Hyperuricemia as a risk factor on cardiovascular events in
Taiwan: The Chin-Shan Community Cardiovascular Cohort
Study. Atherosclerosis 2005;183:147–55.
10. Facchini F, Chen YID, Hollenbeck CB, Reaven GM.
Relationship between resistance to insulin-mediated glucose
uptake, urinary uric acid clearance, and plasma uric acid
concentration JAMA 1991;266:3008–11.
11. Khosla UM, Zharikov S, Finch JL, Nakagawa T, Roncal C, Mu
W, Krotova K, et al. Hyperuricemia induces endothelia
dysfucntion. Kidney Int 2005;67:1739–42.
12. Roy D, Perreault M, Marrette A. Insulin stimulation of glucose
uptake in skeletal muscle and adipose tissues in vivo is NO
dependent. Am J Physiol 1998;274:692–9.
13. Liou TL, Lin MW, Hsiao LC, Tsai TT, Chan WL, Ho LT, Hwu
CM. Is hyperuricemia another facet of the metabolic syndrome?
J Chin Med Assoc 2006;69:104–9.
14. Lee MS, Lin SC, Chang HY, Lyu LC, Tsai KS, Pan WH. High
prevalence of hyperuricemia in elderly Taiwanese. Asia Pac J
Clin Nutr 2005;14:285–92.
